Coronavirus / COVID

The White House said it has secured enough of the Pfizer-BioNTech vaccine supply to offer vaccinations for everyone in this age group.

The company announced the Emergency Use Authorization (EUA) for use with its Spectrum Solutions SpectrumDNA SDNA-1000 collection device on the Amplitude Solution.

The company’s current investigational medical device, Sigyn Therapy, is a novel medical device that is being studied for addressing viral pathogens and bacterial toxins to avoid this massive inflammation onslaught and the potential of sepsis.

Infants, children, and adolescents can carry and spread COVID-19 at the same rate as adults.

The decision comes after supporting data from a "mix and match" trial last week, and may align with emergency authorizations for the Moderna and Janssen booster doses.

One of the infrequently discussed health outcomes that can be impacted by a pandemic is fertility. Using a cross-sectional study, a research team reported incremental increases in infertility during this period.

Comparing 2020 to 2019, investigators saw a reduction in the number of HIV tests, the number of in-person consultations, and new enrollments in care, due to the disruption in HIV care throughout the COVID-19 pandemic.

The VRBPAC committee unanimously voted in favor of the Janssen (Johnson & Johnson) COVID-19 vaccine for use under EUA as a booster dose in individuals 18 years and older at least 2 months after a single dose primary vaccination.

Outside of vaccines, these underutilized therapies are the best defense against severe disease.

Lower rates of COVID-19 vaccination may be due to access, not hesitancy.

The VRBPAC meeting precedes deliberation from the FDA on amending the company's emergency authorization to include booster doses for adult patients.

While receiving a booster of one’s original COVID-19 shot leads to an immune boost, this was heightened among individuals who received a different booster than their primary vaccine.

The FDA suggested that Johnson & Johnson had not conducted an appropriately thorough test to prove its vaccine requires a six-month booster.

New clinical trial is first to describe concomitant administration of any vaccine with either an adenoviral vector or mRNA COVID-19 vaccine.

No ICU admissions or deaths were reported among Native American patients treated with monoclonal antibodies for COVID-19 in a recent study.

The filing is for the first oral antiviral therapy, and is based off its phase 3 trial.

The companies made the request after their recent submission of data to support the emergency use authorization (EUA) in this patient population.

AstraZeneca’s long-acting antibody, AZD7442, would act as a supplement to vaccination and could provide up to a year of protection against symptomatic COVID-19.

US federal health agencies are recommending an additional shot for this diverse patient population, and here on some insights about vaccine efficacy and breakthrough infections in these groups.

This study confirmed reports from the CDC and Israel Ministry of Health that found the Pfizer-BioNTech vaccine waned after 6 months.

Monica McArthur, MD, PhD, discusses why to-be-authorized COVID-19 vaccine doses for children may not be tiered for patient risk as they were for adults.

New late-breaking data illuminate the specific efficacy of the combination monoclonal antibodies.

A new study from IDWeek showed most observed children previously infected with SARS-CoV-2 retained antibodies over 6 months.

The COVID-19 pandemic led people to take hygiene and sanitation more seriously, causing a decrease in C difficile infections.

After an initial hospitalization for COVID-19, some patients may have specific risk factors that increase their likelihood of readmittance.

Major predictors of response were CD4+ count, suppressed viral load, and whether the participant received the Moderna or Pfizer mRNA vaccine.

The Arkansas Health Department’s research showed that, as with the rest of the population, Delta is severely infectious for children.

Investigators examined asymptomatic infection and the duration of viral shedding in symptomatic breakthrough infections in a phase 3 study with the AZD1222 COVID-19 vaccine.

Unpublished, interim phase 3 data show an approximate 50% reduction in hospitalizations and deaths versus placebo. Merck is expediting FDA application for the antiviral drug.